{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:31:57Z","timestamp":1791045117687,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.anl.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T02:12:33Z","timestamp":1729649553000},"page":"1003-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases"],"prefix":"10.1016","volume":"51","author":[{"given":"Mayu","family":"Yamauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ebisumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Teramura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritomo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Yanagiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-3347","authenticated-orcid":false,"given":"Kenji","family":"Okami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2024.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","article-title":"Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients","volume":"36","author":"Sugitani","year":"2012","journal-title":"World J Surg"},{"key":"10.1016\/j.anl.2024.10.002_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.anl.2024.10.002_bib0003","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2024.10.002_bib0004","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.21037\/gs-20-430","article-title":"Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review","volume":"9","author":"Rashid","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.anl.2024.10.002_bib0005","unstructured":"National Comprehensive Cancer. NCCN clinical practice guidelines in oncology thyroid carcinoma. version 2; 2022, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470 Thyroid Carcinoma - Guidelines Detail [Internet]."},{"key":"10.1016\/j.anl.2024.10.002_bib0006","doi-asserted-by":"crossref","first-page":"iv343","DOI":"10.1093\/annonc\/mdu340.10","article-title":"Phase II study of Lenvatinib (Len), a multi-targeted tyrosine kinase inhibitor, in patients (Pts) with all histologic subtypes of advanced thyroid cancer (Differentiated, medullary and anaplastic)","volume":"25","author":"Takahashi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2024.10.002_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2024.10.002_bib0008","first-page":"1184","article-title":"Dabrafenib versus Dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, Phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2024.10.002_bib0009","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.anl.2024.10.002_bib0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2024.10.002_bib0011","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2024.10.002_bib0012","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814624001226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814624001226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:56:26Z","timestamp":1734695786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814624001226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0385814624001226"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2024.10.002","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}